Original Query: ALL
Previous Study | Return to List | Next Study

Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00281762
Recruitment Status : Completed
First Posted : January 25, 2006
Last Update Posted : May 9, 2008
Information provided by:
Regional Hospital Holstebro

Brief Summary:
We wanted to test the hypothesis that prostaglandin inhibition reduces the down regulation of u-AQP-2 induced by fasting

Condition or disease Intervention/treatment Phase
Healthy Drug: NSAID Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Official Title: Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human
Primary Completion Date : January 2007
Study Completion Date : January 2007

Primary Outcome Measures :
  1. FeNa
  2. U-AQP-2

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • (1) Genders; both mal and female
  • (2) Age; 18- 65 years old
  • (3) BMI; below 30
  • (4) Females had to bee in oral contraceptive treatment

Exclusion Criteria:

  • (1) Clinical signs or history of disease in the heart, lungs, kidneys or endocrine organs
  • (2) Abnormal laboratory test (blood haemoglobin, white cell count, platelets, plasma sodium, plasma potassium, plasma creatinine, plasma albumin, plasma bilirubin, plasma alanine aminotransferase, plasma cholesterol and blood glucose)
  • (3) Albuminuria or glucosuria
  • (4) Cancer
  • (5) Arterial hypertension
  • (6) Alcohol abuse
  • (7) Use of tobacco
  • (8) Medical treatment, except oral contraceptives
  • (9) Pregnancy or breast feeding
  • (10) Medicine abuse
  • (11) Donation of blood less than 1 month before the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00281762

Department of Medicine, Holstebro Hospital
Holstebro, Denmark
Sponsors and Collaborators
Regional Hospital Holstebro
Study Chair: Erling B Pedersen, Professor Regional Hospital Holstebro
Principal Investigator: Thomas G Knudsen, MD Regional Hospital Holstebro

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00281762     History of Changes
Other Study ID Numbers: MED.RES.HOS.2005.01.TGK
First Posted: January 25, 2006    Key Record Dates
Last Update Posted: May 9, 2008
Last Verified: May 2008

Keywords provided by Regional Hospital Holstebro:
Urinary concentrating ability

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents